Navigation Links
Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
Date:7/21/2010

apeutics.

About CR845

CR845 is a highly selective, peripherally restricted kappa opioid receptor agonist currently in Phase 2 clinical development for the treatment of postoperative pain.  Randomized, placebo-controlled Phase IIa studies have provided evidence of analgesic efficacy of CR845 administered as a single intravenous dose to women following laparoscopic hysterectomy.  In addition to decreases in reported pain levels, patients receiving CR845 required substantially lower amounts of postoperative opioids for 16 hours, and showed a significant reduction in the incidence of postoperative nausea. Cara expects to complete a Phase 1b repeat dose safety study of CR845 by Q4 this year.  Following this study, the company plans to conduct, a Phase 2b repeat dose efficacy study in laparoscopic hysterectomy patients.  With a total of over 100 human subjects exposed to CR845 to date, there have been no cases of dysphoric reactions or hallucinations as seen previously with centrally-acting kappa opioids.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. In addition to CR845, Cara's current pipeline includes near-term clinical development candidates within multiple proprietary classes of peripherally restricted cannabinoids with preclinical analgesic and anti-inflammatory activity. Cara also plans to develop entirely novel classes of analgesics that emerge from its proprietary GPCR DimerScreen™ technology.

About Rho Ventures

Founded in 1981, Rho Ventures' multi-stage investing strategy focuses on high-growth companies in large markets that disrupt traditional value chains. Rho Ve
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... N.C. , May 1, 2015 The ... for its high price but manufacturer Gilead Sciences overcame ... worldwide pricing, and effective public relations campaigns. ... of less severe side effects propelled the drug to ... 2014, the therapy,s first quarter on the market. But ...
(Date:5/1/2015)... , May 1, 2015 Hitachi Chemical Diagnostics, ... States launch of the ExoComplete™ 96-Well Plate ... easy system for exosome collection to mRNA purification.  The ... Vesicles ("ISEV") Annual Meeting, April 23 – 26, 2015, ... are intended for research use only of molecular biology ...
(Date:5/1/2015)... Markets ( http://www.researchandmarkets.com/research/63gppw/asian_dermatology ) has announced the addition ... End User - Forecast to 2019" report to their ... to grow at a CAGR of 11.3% from 2014 to ... in the Dermatology devices market around 28.8% in 2014 followed ... market holds a high potential for growth in future due ...
Breaking Medicine Technology:New Study Examines Success Lessons of Sovaldi's and Harvoni's Blockbuster Launches 2New Products for Exosome Isolation to mRNA Purification 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 3
... Jan. 26, 2012 Masimo (NASDAQ: MASI ... year financial results for the period ended December 31, 2011, after ... review the results will begin at 1:30 p.m. PT (4:30 p.m. ... Executive Officer, and Mark P. de Raad, Executive Vice President and ...
... Dr. Ira J. Haimowitz, Executive Vice President, Group Director, Intelligence ... at the eMarketing University for Brand Managers, a symposium at ... 2012. The symposium is a full-day course designed ... tactics into their marketing mix. Dr. Haimowitz will be presenting ...
Cached Medicine Technology:Masimo to Report Fourth Quarter and Full Year 2011 Financial Results After Market Close on February 14, 2012 2Masimo to Report Fourth Quarter and Full Year 2011 Financial Results After Market Close on February 14, 2012 3Ira Haimowitz, PhD, EVP, at The CementBloc, to Present on Best Practices in iPad Interactive Selling at 11th Annual ePharma Summit™ 2
(Date:5/1/2015)... BWI (PRWEB) May 02, 2015 The ... It is http://www.thevenetiangracebay.com , and it is elegant ... the stunning white and attractive turquoise hues of Grace ... Google, sixty seven percent of leisure travelers used their ... that smartphones were used in the planning and researching ...
(Date:5/1/2015)... Jusuru International has been awarded the prestigious ... its flagship nutritional supplement, Liquid BioCell™ Life, and the ... new logo, new packaging, new products, and new messaging. ... identify and promote programs that serve as examples of ... Jusuru International for their outstanding accomplishments and contributions to ...
(Date:5/1/2015)... 01, 2015 The Workgroup for ... authority on the use of health IT to create ... contributing resource to the United States Government Accountability Office ... readable cards in Medicare. The report, “ Potential Uses ... was released to the public on Apr. 24, 2015 ...
(Date:5/1/2015)... It’s raining bills on Capitol Hill with members in both ... for telemedicine. , “Such action is unprecedented in ... said Jonathan Linkous, CEO of the American Telemedicine Association (ATA). ... embrace the use of telecommunications in the delivery of care. ... to improve quality, access, equity and affordability of healthcare.”, ...
(Date:5/1/2015)... Ernst & Young (EY) has announced Melanie Rosenthal, ... and Burak Sezen, Co-Founder & CTO of RowdMap, Inc. ... The Year® 2015 Awards in the Ohio Valley Region ... leader in assurance, tax, transaction and advisory services and ... audit companies in the world. The awards program recognizes ...
Breaking Medicine News(10 mins):Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2
... shows screening newborns for biochemical genetic disorders may improve ... researchers say false-positive screening results may increase stress levels ... required a separate test, but now, doctors can screen ... sample of blood by using a device called the ...
... is a joyous experience. But if the experience does not ... the woman. Researchers conducted a study to obtain the views ... the second stage of labor. ,A new study ... the delivery of their child may happen. Researchers say women ...
... women who change partners between the births of their first two ... birth weight than women who have the same partner.// ... the first year of life. The results are the same even ... interval between births, and the decades of birth. ...
... announced what it calls the second heart-related death in ... for a government //investigation into the safety of that ... ,The Physicians Committee for Responsible Medicine states that a ... cardiac arrest while on the Atkins diet. The group ...
... study shows a novel new drug is beneficial for ... and is the first in a new class of ... drug is called cytotoxic T-lymphocyte-associated antigen 4-IgG1 or CTLA4Ig. ... treatment of rheumatoid arthritis. Researchers from Belgium conducted a ...
... It's called partial-breast irradiation, and proponents see it as ... just had a lumpectomy.// ,Thousands of women ... one week or less of radiation after breast cancer ... required for whole-breast irradiation. ,But its long-term benefits ...
Cached Medicine News:Health News:Screening Newborns Questioned 2Health News:Changing Partners may put Expectant Mothers at Risk 2Health News:Partial-Breast Irradiation an Unproven Therapy 2
... 1000 Power Instrument System is a small ... with modular and unitized handpieces.,The head modules ... or pneumatic motor, giving you the flexibility ... the motor. Now you can add instruments ...
... large power line from MicroAire. Our ... AND electric instruments, offering the ultimate ... industry has always wanted with the ... Power Master oscillating saw, Available ...
... Oscillating Saw offers unparalleled power ... to its 14.4V NiMH Rechargeable ... may be rotated into 12 ... plane and will accept any ...
... The SmartDriver System consists of a ... Battery Power, with a wide range of ... variety of orthopedic surgical applications., ,The ... and speed compared to the original Battery ...
Medicine Products: